These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32221808)

  • 1. Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
    Kong Q; Ma X; Zhao X; Chen F; Hou C
    J Thromb Thrombolysis; 2020 Nov; 50(4):942-956. PubMed ID: 32221808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network Meta-Analysis of Ticagrelor for Stroke Prevention in Patients at High Risk for Cardiovascular or Cerebrovascular Events.
    Bálint A; Tornyos D; El Alaoui El Abdallaoui O; Kupó P; Komócsi A
    Stroke; 2021 Aug; 52(9):2809-2816. PubMed ID: 34162232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ticagrelor for prevention of stroke and cognitive impairment in patients with vascular high-risk factors: A meta-analysis of randomized controlled trials.
    Li X; Jia Z; Yan Y
    Int J Cardiol; 2022 Apr; 353():96-102. PubMed ID: 35114201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease-A meta-analysis of randomized clinical trials.
    Cassese S; Ndrepepa G; Byrne RA; Laugwitz KL; Schunkert H; Fusaro M; Alfonso F; Kastrati A
    Am Heart J; 2020 Jan; 219():109-116. PubMed ID: 31756624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials.
    Shao QY; Wang ZJ; Ma XT; Lin XZ; Pan L; Zhou YJ
    BMC Cardiovasc Disord; 2021 Dec; 21(1):574. PubMed ID: 34852763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials.
    von Scheidt M; Bongiovanni D; Tebbe U; Nowak B; Stritzke J; Zhao Q; Zhu Y; Kastrati A; Cassese S; Schunkert H
    Eur J Cardiothorac Surg; 2020 Mar; 57(3):520-528. PubMed ID: 31566205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
    Bhatt DL; Fox K; Harrington RA; Leiter LA; Mehta SR; Simon T; Andersson M; Himmelmann A; Ridderstråle W; Held C; Steg PG;
    Clin Cardiol; 2019 May; 42(5):498-505. PubMed ID: 30788847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; De Luca G
    Atherosclerosis; 2019 May; 284():136-147. PubMed ID: 30884417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
    Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ticagrelor for stroke prevention in patients with vascular risk factors: A systematic review and meta-analysis.
    Malhotra K; Goyal N; Kasunich AS; Sheth SA; Katsanos AH; Alexandrov AV; Tsivgoulis G
    J Neurol Sci; 2018 Jul; 390():212-218. PubMed ID: 29801891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial.
    Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW
    Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
    De Schryver EL; Algra A; van Gijn J
    Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
    Bundhun PK; Shi JX; Huang F
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
    Tang XF; Fan JY; Meng J; Jin C; Yuan JQ; Yang YJ
    Atherosclerosis; 2014 Apr; 233(2):568-578. PubMed ID: 24534451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
    Bansilal S; Bonaca MP; Cornel JH; Storey RF; Bhatt DL; Steg PG; Im K; Murphy SA; Angiolillo DJ; Kiss RG; Parkhomenko AN; Lopez-Sendon J; Isaza D; Goudev A; Kontny F; Held P; Jensen EC; Braunwald E; Sabatine MS; Oude Ophuis AJ
    J Am Coll Cardiol; 2018 Feb; 71(5):489-496. PubMed ID: 29406853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    Steg PG; Bhatt DL; Simon T; Fox K; Mehta SR; Harrington RA; Held C; Andersson M; Himmelmann A; Ridderstråle W; Leonsson-Zachrisson M; Liu Y; Opolski G; Zateyshchikov D; Ge J; Nicolau JC; Corbalán R; Cornel JH; Widimský P; Leiter LA;
    N Engl J Med; 2019 Oct; 381(14):1309-1320. PubMed ID: 31475798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
    Gouya G; Arrich J; Wolzt M; Huber K; Verheugt FW; Gurbel PA; Pirker-Kees A; Siller-Matula JM
    Stroke; 2014 Feb; 45(2):492-503. PubMed ID: 24368560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of short-term dual- versus mono-antiplatelet therapy in patients with ischemic stroke or TIA: a meta-analysis of 10 randomized controlled trials.
    Liu Y; Fei Z; Wang W; Fang J; Zou M; Cheng G
    J Neurol; 2016 Nov; 263(11):2247-2259. PubMed ID: 27541045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.